Last $13.24 USD
Change Today +0.20 / 1.53%
Volume 12.8K
As of 5:20 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

ardelyx inc (ARDX) Snapshot

Open
$13.01
Previous Close
$13.04
Day High
$14.16
Day Low
$13.01
52 Week High
07/7/14 - $21.60
52 Week Low
08/7/14 - $11.37
Market Cap
245.4M
Average Volume 10 Days
32.3K
EPS TTM
--
Shares Outstanding
18.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARDELYX INC (ARDX)

Related News

No related news articles were found.

ardelyx inc (ARDX) Related Businessweek News

No Related Businessweek News Found

ardelyx inc (ARDX) Details

Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 and is headquartered in Fremont, California.

36 Employees
Last Reported Date: 08/8/14
Founded in 2007

ardelyx inc (ARDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $416.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $310.0K
Vice President of Drug Development
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

ardelyx inc (ARDX) Key Developments

Ardelyx, Inc. Announces Retirement of Dominique Charmot as Chief Scientific Officer, Effective from December 23, 2014

Ardelyx, Inc. announced that Dominique Charmot, Ph.D., the company's Chief Scientific Officer, has announced his retirement from Ardelyx, effective December 23, 2014. Dr. Charmot cited personal reasons for his departure, including his desire to spend more time with his family.

Ardelyx, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Ardelyx, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $9,137,000, income from operations of $2,751,000, income before provision for income taxes of $3,753,000, net income and comprehensive income of $3,753,000 or $0.18 per diluted share compared to the total revenue of $7,291,000, loss from operations of $851,000, loss before provision for income taxes of $855,000, net loss and comprehensive loss of $891,000 or $0.81 per diluted share for the same quarter a year ago. For the six months period, the company reported total revenue of $17,687,000, income from operations of $2,287,000, income before provision for income taxes of $682,000, net income and comprehensive income of $682,000 compared to the total revenue of $13,847,000, loss from operations of $1,261,000, loss before provision for income taxes of $1,290,000, net loss and comprehensive loss of $1,361,000 or $1.27 per diluted share for the same period a year ago.

Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM

Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Michael G. Raab, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDX:US $13.24 USD +0.20

ARDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARDX.
View Industry Companies
 

Industry Analysis

ARDX

Industry Average

Valuation ARDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARDELYX INC, please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.